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Manuscript received July 7, 2015 and accepted August 4, 2015AbstractAfter demonstration of the antihypertensive efficacy of the combination of the beta-blocker nebivolol and the angiotensin recep-
tor blocker valsartan in an 8-week, randomized, placebo-controlled trial (N¼ 4161),we now report the effects of this treatment on
the renin-angiotensin-aldosterone system in a substudy (n¼ 805). Plasma renin activity increasedwith valsartan (54%–73%) and
decreasedwith nebivolol (51%–65%) and the combination treatment (17%–39%). Plasma aldosterone decreasedwith individual
treatments (valsartan, 11%–22%; nebivolol, 20%–26%), with the largest reduction (35%) observed with maximum combination
dose (20 mg nebivolol/320 mg valsartan). Baseline ln(plasma renin activity) correlated with the 8-week reductions in 24-hour
systolic and diastolic BP following treatments with the combination (all doses combined, P¼ .003 and P< .001) and nebivolol
(both, P < .001), but not with valsartan. Baseline ln(aldosterone) correlated with 24-hour systolic and diastolic BP reductions
following combination treatment only (P < .001 and P ¼ .005). The implications of the renin-angiotensin-aldosterone system
effects of this beta blocker-angiotensin receptor blocker combination should be explored further. J Am Soc Hypertens
2015;9(11):845–854.  2015 The Authors. Published by Elsevier Inc. on behalf of American Society of Hypertension. This
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Plasma renin activity (PRA) was one of the earlier
biomarkers of hypertension and drew attention to the role
of the renin-angiotensin-aldosterone system (RAAS) in
the pathophysiology of hypertension.1 Renin, produced
in the juxtaglomerular cells of the kidney, is the rate-
limiting enzyme in the renin-angiotensin system and is
responsible for converting angiotensinogen to angiotensin
I.1 Angiotensin I is subsequently processed by the
angiotensin I-converting enzyme to angiotensin II, the
main effector peptide of the system.1
The emergence of antihypertensive drugs that perturb the
RAAS provided an opportunity to further explore the
system’s role in blood pressure (BP) regulation. It was
reasoned that patients with higher baseline PRAs would
have a greater reduction in BP to renin-angiotensin-
aldosterone system-blocking drugs than patients with lower
PRA. In addition, it was proposed that PRA could be useful
in characterizing patients with hypertension who had
vasoconstriction as the principal mechanism responsible
for BP elevation. This strategy has been tested many times,
but with inconsistent results.2,3
A recently completed large randomized trial (N¼ 4161) in
individuals with hypertension demonstrated that an
antihypertensive single-pill combination (SPC) consisting
of nebivolol, a b1-selective vasodilatory b-blocker,
4 and
valsartan,5 an angiotensin II receptor blocker (ARB), is
more efficacious in reducing BP than the individual drugs.6
In a substudy of that trial (n ¼ 805), we measured PRA
and aldosterone concentrations, providing us with an
opportunity to examine whether these measurements could
help explain the effects of treatment on BP measured by
ambulatorymonitoring. In the followingwe report the results
of that substudy.MethodsStudy DesignThe details of study design were reported previously.6
Briefly, the study was a phase 3, multicenter, randomized,
double-blind, placebo-controlled, parallel-group, dose-
titration trial (NAC-MD-01; NCT01508026) in which
participants, after a 1-week screening period, entered a
6-week single-blind placebo run-in phase, followed by an
8-week double-blind treatment period. The participants
were randomized (2:2:2:2:2:2:2:1) to 4 weeks of double-
blind treatment with a nebivolol-valsartan SPC (5/80,
5/160, or 10/160 mg/day), nebivolol monotherapy (5 or
20 mg/day), valsartan monotherapy (80 or 160 mg/day),
or placebo. Dosages were doubled at the beginning of
week 5 to SPC 10/160, 10/320, or 20/320 mg/day, nebivolol
10 or 40 mg/day, or valsartan 160 or 320 mg/day. After
8 weeks of double-blind treatment, the study drug dosewas tapered over a 1-week double-blind down-titration
phase.ParticipantsEligible participants were men or women 18 years of
age, diagnosed with Stage 1 or 2 hypertension (JNC7
criteria7), and with diastolic BP (DBP) measurements of
95 mm Hg and <110 mm Hg (untreated) or 90 mm
Hg and <110 mmHg (treated) at screening, and a seated
pulse rate of 55 bpm. Participants were also required to
have normal or clinically nonsignificant results of physical
examination, laboratory tests, and electrocardiogram at
screening. Key exclusion criteria were secondary hyperten-
sion, severe hypertension (SBP 180 mm Hg or DBP
110 mm Hg), current treatment with 4 antihypertensive
medications (including components of the SPC), contrain-
dication to discontinuing antihypertensive treatment, upper
arm circumference >42 cm, the presence of symptomatic
coronary artery disease, reactive airways disease, chronic
obstructive pulmonary disease, second- or third-degree
heart block or sick sinus syndrome, type 1 diabetes, poorly
controlled type 2 diabetes (HbA1C  8%), uncontrolled
thyroid disease within 3 months of screening, and preg-
nancy or breastfeeding. In addition, shift workers were
excluded from the substudy.Biomarkers-Ambulatory Blood Pressure
Monitoring SubstudyPredose blood samples for the assessment of PRA and
aldosterone were collected at Baseline and at weeks 4
and 8. All samples were immediately frozen in a mixture
of ethanol and ice and shipped on dry ice to the central
laboratory (Keystone Bioanalytical Inc., North Wales, PA,
USA). PRA was determined by means of an enzyme-
linked immunosorbent assay and aldosterone levels were
determined using high performance liquid chromatography
coupled with tandem mass spectrometry. Ambulatory blood
pressure monitoring (ABPM) measurements were recorded
at baseline and at the end of week 8; the devices were
applied between 8 AM and 10 AM on the nondominant
arm and the data were processed by BioClinica, Inc.
(Princeton, NJ, USA).Data AnalysisChanges in 24-hour DBP and SBP in all groups were
prespecified as additional efficacy parameters. Analyses
were performed based on the intention-to-treat (ITT)
population in the ABPM substudy, using the last
observation carried forward approach to impute missing
data. Treatment groups were compared using an analysis
of covariance model with treatment group and diabetes
status as factors and baseline value as a covariate; nominal
Figure 1. Baseline-to-endpoint changes in 24-hour ABPM parameters (ITT, LOCF, ANCOVA) (A) DBP; (B) SBP. **P < .01;
***P < .001. ABPM, ambulatory blood pressure monitoring; ANCOVA, analysis of covariance; DBP, diastolic blood pressure; ITT,
intent-to-treat population; LOCF, last observation carried forward; LS, least squares; LSM, least squares mean; Neb, nebivolol; Pbo,
placebo; SBP, systolic blood pressure; SEM, standard error of the mean; Val, valsartan.
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active treatment groups by biomarker level quartiles
(Figure 4) were performed using the same model.
Protocol-based biomarker analyses were performed by
means of descriptive statistics, using the ITT population
in the substudy and the last observation carried forward
approach for imputation of missing data. Post hoc compar-
isons were performed using a general linear model with
treatment group and diabetes status as class variables and
log-transformed baseline values as a covariate; nominal
P-values are provided. Post hoc correlations between
24-hour, daytime, and nighttime DBP and SBP changes
in pooled active treatment groups and natural logarithm
values of PRA and aldosterone concentration at baseline
(Table 2) were assessed by means of Pearson’s R.
ResultsPatient CharacteristicsOf 4161 randomized participants, 805 (19.3%) partici-
pated in the substudy. Baseline characteristics of the
ITT population in the ABPM substudy (N ¼ 797) are
summarized in Table 1.ABPM AnalysesFrom baseline to week 8, SPC 20/320 was significantly
more effective than Val 320 in reducing both 24-hour
DBP (least squares mean difference [LSMD] [95% CI]:
4.6 [6.6, 2.5] mm Hg, P < .001) and 24-hour SBP
(5.1 [8.4, 1.8] mm Hg, P ¼ .003), but not more
than Neb 40 (DBP: 1.6 [3.7, 0.6] mm Hg, P ¼ .149;
SBP: 2.1 [5.4, 1.3] mm Hg, P ¼ .231; Figure 1).Additional analyses suggest that SPC 10/160 was signi-
ficantly more effective than both of its component
monotherapies in reducing 24-hour DBP and more effective
than Val 160 in reducing 24-hour SBP (Figure 1).Biomarker AnalysesThe geometric mean PRAvalues at baseline and endpoint
are presented in Figure 2A. After 8 weeks of double-blind
treatment, PRA levels in the groups treated with Val 160
and Val 320 increased by 53.8% and 72.8%, respectively,
and decreased in the groups treated with nebivolol (by
51.3% [10 mg/day] and 65.4% [40 mg/day]) and the SPCs
(from 3.2% to 39.0%; Figure 2B). A post hoc analysis re-
vealed significant differences in PRA geometric mean ratios
between SPCs 20/320 and 10/320 versus their monotherapy
components, plus SPC 10/160 versus Val 160 (Figure 2B).
The geometric mean aldosterone concentrations at
baseline and endpoint are summarized in Figure 3A. After
8 weeks of double-blind treatment, aldosterone level in the
placebo group increased by 17.1%, compared with the
baseline; in all other groups aldosterone levels decreased,
from 11.1% to 35.1%. The greatest decrease was in the
SPC 20/320 group, which exceeded the reductions
observed in the Neb 40 group and the Val 320 group by
32.8% and 59.0%, respectively (Figure 3B). A post hoc
analysis revealed that the difference in aldosterone change
from baseline between SPC 20/320 and Val 320 was
statistically significant (Figure 3B).
Post hoc analysis of pooled active treatment groups
revealed that natural logarithm (ln) baseline levels of
PRA were significantly correlated with 24-hour and
daytime BP changes at week 8 in participants treated
Figure 2. PRA levels and changes from baseline (ITT, LOCF) (A) Baseline and Endpoint Concentrations; (B) Baseline-to-Endpoint
Change. ***P < .001. ITT, intent-to-treat population; LOCF, last observation carried forward; Neb, nebivolol; PRA, plasma renin
activity; SPC, single-pill combination of nebivolol and valsartan; Val, valsartan.
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addition, 24-hour, daytime, and nighttime BP changes
(except nighttime DBP) were significantly correlated with
natural logarithm baseline levels of aldosterone in partici-
pants treated with the SPCs, but not with the monotherapies
(Table 2).
Twenty-four-hour DBP changes by baseline quartiles of
PRA and aldosterone levels are shown in Figure 4.
Discussion
As expected, administration of valsartan monotherapy
resulted in a dose-dependent increase in PRA, which is a
well-documented effect of ARB treatment.8,9 In contrast,nebivolol monotherapy decreased PRA in a dose-
dependent manner, which is consistent with previously
published data on nebivolol and other b-blockers.10,11 As
hypothesized, the nebivolol-valsartan combination was
associated with a reduction in PRA, which is likely a result
of nebivolol-induced attenuation of the valsartan-induced
increase, and consistent with results of a single-dose study
in healthy adult men given monotherapy or combination
therapy consisting of valsartan and the b1-selective antago-
nist atenolol.12 To the best of our knowledge, our study is
the first to assess the combined effect of a b-blocker and
an ARB on PRA and aldosterone, and the first to assess
the antihypertensive effect of that combination in the
context of baseline biomarker levels.
Figure 3. Aldosterone levels and changes from baseline (ITT, LOCF) (A) Baseline and Endpoint Concentrations; (B) Baseline-to-
Endpoint Change. *P < .05. ITT, intent-to-treat population; LOCF, last observation carried forward; Neb, nebivolol; PRA, plasma renin
activity; SPC, single-pill combination of nebivolol and valsartan; Val, valsartan.
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RAAS by the combination of nebivolol and valsartan. In
fact, the decrease in PRA is regarded as a primarymechanism of BP lowering with b-blockers.13 Results of
our study cast light on results of another trial, in which
patients with compromised renal function were treated
Figure 4. Baseline-to-endpoint changes in 24-hour DBP by baseline PRA and ALDO quartiles, pooled treatment groups (ITT, LOCF,
ANCOVA) (A) 24-h DBP by PRA Quartile; (B) 24-h DBP by ALDO Quartile. *P < .05; **P < .01; ***P < .001. ABPM, ambulatory
blood pressure monitoring; ALDO, aldosterone; ANCOVA, analysis of covariance; DBP, diastolic blood pressure; ITT, intent-to-treat
population; LOCF, last observation carried forward; LS, least squares; SBP, systolic blood pressure; SEM, standard error of the
mean; Q, quartile.
Table 1
Demographic and clinical characteristics at baseline, biomarkers-ABPM substudy (ITT population)
Characteristic Placebo SPC, Final Dosage (mg/day) Nebivolol, Final Dosage
(mg/day)
Valsartan, Final Dosage
(mg/day)
(n ¼ 52) 10/160
(n ¼ 107)
10/320
(n ¼ 108)
20/320
(n ¼ 110)
10
(n ¼ 105)
40
(n ¼ 107)
160
(n ¼ 103)
320
(n ¼ 105)
Age (years)* 49.4  11.1 51.5  10.0 51.0  8.7 50.7  10.2 51.5  9.1 51.4  10.8 52.2  9.6 50.6  9.1
Meny 32 (61.5) 53 (49.5) 65 (60.2) 67 (60.9) 62 (59.0) 63 (58.9) 56 (54.4) 63 (60.0)
Racey
White 36 (69.2) 84 (78.5) 90 (83.3) 92 (83.6) 85 (81.0) 92 (86.0) 88 (85.4) 84 (80.0)
Black 13 (25.0) 19 (17.8) 14 (13.0) 14 (12.7) 18 (17.1) 14 (13.1) 12 (11.7) 15 (14.3)
Other 3 (5.8) 4 (3.7) 4 (3.7) 4 (3.6) 2 (1.9) 1 (0.9) 3 (2.9) 6 (5.7)
Ethnicityy
Hispanic 18 (34.6) 46 (43.0) 40 (37.0) 42 (38.2) 31 (29.5) 36 (33.6) 33 (32.0) 35 (33.3)
Non-Hispanic 34 (65.4) 61 (57.0) 68 (63.0) 68 (61.8) 74 (70.5) 71 (66.4) 70 (68.0) 70 (66.7)
Weight (kg)* 95.6  22.7 91.9  19.0 93.4  17.6 92.8  21.0 94.4  20.2 92.5  22.2 92.4  19.4 94.8  20.4
BMI (kg/m2)* 32.5  5.8 32.4  6.0 32.4  5.8 32.0  6.4 32.4  5.5 32.0  6.2 32.2  5.6 32.9  6.2
Type 2
diabetesy
7 (13.5) 14 (13.1) 21 (19.4) 19 (17.3) 14 (13.3) 17 (15.9) 17 (16.5) 15 (14.3)
ABPM Values
24-h SBP
(mmHg)*,z
137.3  14.9 142.9  14.3 142.8  13.4 142.2  13.5 138.9  10.6 140.8  13.9 142.6  14.6 141.8  13.1
24-h DBP
(mmHg)*,z
85.8  9.6 88.1  9.3 88.7  9.1 87.3  9.0 86.9  8.6 86.6  9.3 87.8  9.6 88.6  9.3
ABPM, ambulatory blood pressure monitoring; BMI, body mass index; DBP, diastolic blood pressure; ITT, intent-to-treat population;
SD, standard deviation; SBP, systolic blood pressure; SPC, single-pill combination of nebivolol-valsartan.
ABPM values are based on the numbers of patients who had measurements at baseline and at least one postbaseline visit (placebo,
n ¼ 39; SPC 10/160, n ¼ 78; SPC 10/320, n ¼ 83; SPC 20/320, n ¼ 86; nebivolol 10, n ¼ 87; nebivolol 40, n ¼ 77; valsartan 160,
n ¼ 78; valsartan 320, n ¼ 82).
* Data presented as mean  SD.
yData presented as n (%).
z Intent-to-treat population.
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Table 2
Correlation between baseline biomarker values and BP changes
from baseline at week 8, pooled treatment groups (ITT, LOCF)
ln(PRA) ln(ALDO)
Pearson’s R
P-Value
Pearson’s R
P-Value
24-hour DBP change
Pbo .113 .066
.511 .704
Neb pooled .331 .003
<.001 .974
Val pooled .101 .073
.216 .374
SPC pooled .209 .181
<.001 .005
24-hour SBP change
Pbo .034 .120
.842 .486
Neb pooled .344 .016
<.001 .844
Val pooled .009 .063
.908 .439
SPC pooled .189 .217
.003 <.001
Daytime DBP change
Pbo .157 .020
.360 .906
Neb pooled .332 .012
<.001 .878
Val pooled .118 .127
.146 .121
SPC pooled .232 .186
<.001 .004
Daytime SBP change
Pbo .080 .051
.641 .768
Neb pooled .330 .013
<.001 .870
Val pooled .002 .109
.984 .181
SPC pooled .208 .225
.001 <.001
Nighttime DBP change
Pbo .055 .167
.749 .331
Neb pooled .207 .029
.008 .720
Val pooled .032 .056
.693 .496
SPC pooled .103 .122
.108 .061
Nighttime SBP change
Pbo .104 .256
.546 .132
Neb pooled .279 .020
<.001 .800
Val pooled .031 .049
(continued)
Table 2 (continued )
ln(PRA) ln(ALDO)
Pearson’s R
P-Value
Pearson’s R
P-Value
.709 .551
SPC pooled .107 .151
.094 .020
All P-values are presented as italic, and those <.05 are bold,
as intended.
ABPM, ambulatory blood pressure monitoring; ALDO, aldoste-
rone; BP, blood pressure; DBP, diastolic blood pressure; SPC,
single-pill combination (nebivolol-valsartan fixed-dose combina-
tion); ITT, intent-to-treat population; ln, natural logarithm;
LOCF, last observation carried forward; Neb, nebivolol; Pbo,
placebo; SBP, systolic blood pressure; Val, valsartan.
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renin release: aliskiren, a direct renin inhibitor, and
valsartan.14 The aliskiren-valsartan combination did not
result in a favorable clinical response, perhaps due to an
excessive increase in PRA,15,16 an effect that contrasts
strongly with the reduction in PRA observed with dual
RAAS blockade in the present study. In fact, an increase
in PRA may signal an unfavorable cardiovascular outcome,
independent of any BP reduction.17,18 It is entirely possible
that the beta blocker-ARB combination we studied is a
desirable approach to dual blockade of the renin-
aldosterone axis.
The effect of the nebivolol-valsartan combination on
aldosterone appears to be more complex. Nebivolol mono-
therapy has been shown to reduce plasma aldosterone levels
in individuals with hypertension,10 which is consistent with
our data. Reductions in aldosterone also occur with valsar-
tan treatment, but a phenomenon known as aldosterone
‘‘breakthrough’’ or ‘‘escape’’—a return toward pre-RAAS
inhibitor treatment levels after an initial decrease1,19—
has been observed in a subset of patients receiving ARB
or angiotensin I-converting enzyme inhibitor treatment.19
This aldosterone rebound with ARB treatment might be
due to the inhibition of the angiotensin II-activated negative
feedback loop, resulting in increased angiotensinogen
synthesis.1 In our study population, however, aldosterone
levels decreased with valsartan monotherapy, at least
during the 8-week period of observation. Indeed, all active
treatments in our study were associated with a decrease in
aldosterone levels, with the greatest effects during
combination therapy, suggesting a potential combined
effect. In addition, due to their opposing effects on renin
release, nebivolol and valsartan given in combination might
mitigate aldosterone breakthrough, if indeed this phenome-
non occurs. However, such a possibility would have to be
tested in appropriately designed clinical trials.
Perhaps the most interesting finding in this study—based
on a post hoc analysis—was that the amplitude of the
852 T.D. Giles et al. / Journal of the American Society of Hypertension 9(11) (2015) 845–854BP-lowering effects of the combined nebivolol and valsar-
tan treatment correlated with baseline values for both PRA
and aldosterone. The finding with PRA, as discussed
earlier, has been reported with other therapies, though
usually with just one drug. The finding with aldosterone,
however, appears to be unique, and underscores that this
type of dual RAAS blockade might exert an important
part of its effects through inhibition of aldosterone in
patients whose hypertension may be at least partly
dependent on the direct BP-raising effects of aldosterone.
If so, this mechanism of action may be of importance in
the treatment of patients with so-called treatment-resistant
hypertension, in whom excess aldosterone may be an
important factor in sustaining high BP levels.20 It would
be of considerable interest to prospectively measure
the antihypertensive efficacy of the nebivolol-valsartan
combination in such patients.Acknowledgments
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